Clinical Trial Update: A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

View source ↗

Summary

This is a completed sub-study of Miricorilant in patients with presumed nonalcoholic steatohepatitis (NASH). The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Miricorilant (CORT118335)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Nonalcoholic Steatohepatitis (NASH) | Status: COMPLETED